AC Immune: Report of foreign issuer
Press release · 05/24 21:09
Biogen’s new Alzheimer’s drug to raise annual Medicare costs by up to $5B – study
Seeking Alpha · 05/14 16:00
KEY, NNOX and CMA are among pre-market gainers
Seeking Alpha · 05/05 12:33
HC Wainwright & Co. Reiterates AC Immune (ACIU) Buy Recommendation
NASDAQ · 05/01 19:00
SVB Securities Sticks to Its Buy Rating for AC Immune SA (ACIU)
TipRanks · 05/01 14:56
HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
Benzinga · 05/01 10:24
H.C. Wainwright Sticks to Its Buy Rating for AC Immune SA (ACIU)
TipRanks · 05/01 10:15
AC Immune GAAP EPS of -CHF0.21
Seeking Alpha · 04/28 11:31
AC Immune SA (ACIU) Receives a Buy from SVB Securities
TipRanks · 04/21 12:25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Assembly Biosciences (ASMB), AC Immune SA (ACIU) and Biomea Fusion (BMEA)
TipRanks · 04/19 10:30
AC Immune Granted U.S. Patent #11623931: Bicyclic Compounds For Diagnosis And Therapy
Benzinga · 04/11 10:19
Tallying Up My 2022 Tax Loss Selling Portfolio Results
Seeking Alpha · 04/03 12:55
SVB Securities Sticks to Their Buy Rating for AC Immune SA (ACIU)
TipRanks · 03/20 13:47
AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures
Seeking Alpha · 03/18 13:00
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Paratek Pharmaceuticals (PRTK) and AC Immune SA (ACIU)
TipRanks · 03/17 10:30
AC Immune Non-GAAP EPS of -CHF 0.81, revenue of CHF 3.9M
Seeking Alpha · 03/16 11:57
BRIEF-AC Immune Reports Full Year 2022 Financial Results And Provides Corporate Update
Reuters · 03/16 11:30
AC Immune FY Adjusted EPS CHF(0.81) Up From CHF(0.99) YoY, Sales CHF3.94M
Benzinga · 03/16 11:09
Earnings Scheduled For March 16, 2023
Benzinga · 03/16 10:59
Webull provides a variety of real-time ACIU stock news. You can receive the latest news about AC Immune through multiple platforms. This information may help you make smarter investment decisions.
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.